Keeping Track: Clovis Completes NDA; FDA Clears 3D-Printed Antiepileptic But Declines Preservative-Free Eye Drug
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
US FDA Progress Report Highlights Biomarkers, Continuous Manufacturing, Antibiotic Testing
Agency documents its regulatory science accomplishments to advance product development and manufacturing and ensure the safety and effectiveness of marketed products.
Minimal Residual Disease Gains Max US FDA AdComm Support For Myeloma Trials
The US FDA’s Oncologic Drugs Advisory Committee unanimously agreed that accelerated approvals should be enabled by multiple myeloma trials using MRD as a surrogate endpoint.
Minimal Residual Disease Inches Closer To Supporting Myeloma Accelerated Approvals
US FDA’s oncology advisory committee will discuss two meta-analyses supporting use of MRD as a surrogate endpoint to support accelerated approval in multiple myeloma trials.